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Abstract 
Melanocytic nevi represent a widespread cutaneous finding. Nevertheless, the presence of 
mycosis fungoides and melanocytic nevi in the same location is an extremely rare event. We 
report the case of a patient affected by mycosis fungoides and treated with PUVA therapy, 
with complete remission of the disease. Eight years after therapy discontinuation, he 
presented epidermal scaling and an erythematous perinevic halo on 3 old melanocytic 
lesions, the clinical aspect of which was highly suggestive for Meyerson nevi. The histological 
and immunohistochemical examination of an excised melanocytic lesion revealed 
histological features consistent with the diagnosis of mycosis fungoides superimposed on 
junctional melanocytic nevi. The finding of patches of mycosis fungoides superimposed on 
melanocytic nevi is a rare event; the confounding clinical appearance with eczematous 
changes around a pre-existing nevus may recall the halo dermatitis known as Meyerson 
phenomenon; this highlights the importance of clinical and histological examination to make 
the correct diagnosis of dermatological diseases. 
 
Introduction 
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma 
(CTCL) and is characterized by malignant proliferation of skin-homing CD4+ T cells of  
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unknown etiology. Clinically, eczematous and/or psoriasiform patches and plaques are 
the most common presentation, which may progress to cutaneous tumors or 
involvement of lymph nodes and visceral organs [1]. 
Despite representing over two thirds of cutaneous lymphoma, MF is not a common 
disease and its incidence has been estimated to 0.36/105 person-years in the USA and 
0.5/105 in the Western world [2]. Furthermore, MF has been described in patients with 
other hematological disorders or malignant solid tumors, and patients with MF have a 
higher frequency (6–16%) of second (non-hematological) malignancies, such as 
melanoma, than the general population [3]. MF has also been described in the context 
of non-melanoma skin carcinomas or as collision tumors with common or dysplastic 
melanocytic nevi, even if it is a rare event [4, 5]. 
Meyerson nevus is a melanocytic nevus with an associated acute inflammatory 
response, producing a peripheral ring of erythema and scale (Meyerson phenomenon). 
We report the case of a patient with MF treated with PUVA therapy who experienced a 
disease relapse only on pre-existing melanocytic nevi, with the clinical features 
mimicking Meyerson phenomenon. 
Case Report 
A 63-year-old man presented with multiple, slightly pruritic, erythematous-scaling patches with a 
cigarette paper-like appearance on his trunk, buttocks, and lower limbs, characterized by a relapsing 
clinical course over the last 5 months and resistance to common topical therapies. 
Histological examination of a cutaneous biopsy of the trunk revealed a band-like lymphocytic 
infiltrate at the dermoepidermal junction, with a perivascular localization in the superficial dermis 
and diffuse interstitial infiltrates in the papillary dermis. The presence of lymphocytic exocytosis with 
nuclear atypia and prominent intraepidermal lymphocytes and the absence of spongiosis were 
documented. Epidermal parakeratosis was evident. 
Immunohistochemistry showed a CD2+, CD3+ and CD4+ lymphocytic infiltrate, with low CD7 
expression, while polymerase chain reaction (PCR) analysis revealed a clonal rearrangement of T-cell 
receptor-γ (TCR-γ). A diagnosis of MF was made. The patient presented with patch disease involving 
>10% of the body surface area, without lymph node and visceral involvement. In consideration of 
these findings, a diagnosis of an early-stage MF (IB) was rendered [6]. 
The execution of an accurate hematological, biochemical, and imaging screening allowed the 
exclusion of extracutaneous involvement. According to EORTC guidelines [6], the patient was 
therefore treated with PUVA therapy, and a clinical remission was documented after 30 treatments, 
corresponding to a cumulative dose of 195 J/cm2. 
The follow-up showed a lasting remission of the disease over the next 8 years. Yet, the last physical 
examination evidenced the presence of epidermal scaling and an erythematous perinevic halo on 3 
long-standing melanocytic lesions on his trunk; the clinical appearance of the lesions was highly 
suggestive of Meyerson nevi (fig. 1). 
One of the lesions was surgically removed for histological examination with complete elliptical 
excision followed by primary suture. The nevus was mostly composed of melanocytic nests at the 
dermoepidermal junction, associated with particularly abundant band-like lymphocytic infiltrates 
obscuring the dermoepidermal junction, and characterized by focal epidermotropism of 
hyperchromatic, enlarged, convoluted lymphocytes (fig. 2a–c). Immunohistochemistry confirmed S-
100 protein-positive staining in melanocytic nevus cells (fig. 2d), while the infiltrate was 
predominantly composed of CD3+, CD4+ and CD5+ T cells (fig. 2e, f), with low CD7 expression. These 
findings were consistent with the diagnosis of MF superimposed on a junctional melanocytic nevus.  
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The other two lesions were therefore surgically removed in the same way as described for the 
previous lesion, and all specimens revealed the same histological features, confirming the diagnosis of 
MF associated with junctional melanocytic nevi. No further treatment was rendered except surgical 
excision. 
The patient is still in fairly good clinical condition without MF cutaneous lesions and the remission 
has so far lasted 2 years. 
Discussion 
Mycosis fungoides represents the most common type of CTCL, comprising 50% of 
CTCLs with a yearly incidence of 0.36 cases per 100,000 of the population; which has 
remained constant over the past decade, thus being a rare disease [7]. On the contrary, 
melanocytic nevi represent a widespread cutaneous finding. Nevertheless, the finding 
of MF and melanocytic nevi in the same location is a rare event; to our knowledge, only 
2 cases have previously been described in the literature [5]. In the case we report, new 
MF lesions relapsed on pre-existing junctional nevi after a PUVA-induced long-lasting 
remission. 
As described by Boyd and Rapini [8], melanocytic lesions appear to be the most 
common component of cutaneous collision tumors, followed by basal-cell carcinomas 
and seborrheic keratoses. 
McNiff and Glusac [5] reported the first 2 descriptions of a collision between MF and 
melanocytic neoplasms. In the first case, the occurrence of MF in a congenital nevus 
was associated with a halo phenomenon restricted to the affected region, thus raising 
questions about the role of CD8+ cytotoxic T cells in both processes (halo phenomenon 
and juvenile MF); in the other patient, nests of two morphologies (lymphocytic and 
melanocytic) in the same specimen presented an unusual histological picture with a 
confounding and possibly pseudomalignant appearance [5]. 
In our case, the clinical differential diagnosis of MF superimposed on melanocytic 
lesions includes, firstly, Meyerson phenomenon. In particular, this condition refers to a 
well-documented inflammatory reaction described in a variety of cutaneous lesions, 
including the original description in nevocellular nevi [9]. Although there are many 
hypotheses for the pathogenesis of Meyerson phenomenon, its etiology remains 
unclear, and it is still a rare event, characterized by a benign and non-recurring course 
[10]. 
On the other hand, mycosis fungoides represents a cancer of T cells whose behavior 
is dominated by their propensity to go to the skin, to be activated and persist in an 
activated state, and then achieving their peculiar clonal dominance [11]. 
PUVA treatment for MF acts by stimulating CD4+ T cells to produce Th1 cytokines 
IFN-γ and IL-2, which activate tumor-specific CD8+ cytotoxic T lymphocytes (CTL). 
PUVA-treated CD4+ T cells contemporarily activate monocytes to produce cytokines, 
such as IL-8, and to become tumor antigen-presenting cells for the development of 
CD8+ CTL, which finally lyse CTCL cells by overcoming suppression caused by Th2 
cytokines released from CTCL cells [12, 13]. These complex mechanisms suggest that 
PUVA treatment is not merely cytotoxic, but induces activational events in different cell 
types, and melanocytes are targeted too.  
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It has been demonstrated that UV-induced molecular effects on melanocytes reflect 
cellular responses that might cause signal transduction and activation of intracellular 
stress response mechanisms, thus controlling cell communication and immune 
responses [14, 15]. 
These observations may suggest a trigger role of UVA in eliciting a particular 
response driven by melanocytes and resulting in a delayed relapse of the disease; at the 
same time, the collision of these processes may likely represent a casual finding, 
because our patient presented a localized relapse of MF, not involving the majority of 
melanocytic nevi, and at the time of relapse, several years had passed since PUVA 
therapy had been discontinued. 
In summary, we report an extremely rare occurrence of MF superimposed on 
melanocytic nevi, and the lack of similar cases in the literature does not allow concrete 
explanations of this bizarre association. This report highlights the importance of 
clinical examination and appropriate employment of histology and 
immunohistochemistry, which together can lead to the right diagnosis of 
dermatological diseases. 
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Fig. 1. Melanocytic nevi with epidermal scaling and an erythematous perinevic halo. 
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Fig. 2. a–c A dense infiltrate at the dermoepidermal junction composed by lymphocytes with 
hyperchromatic nuclei, exocytosis, and focal epidermotropism, together with junctional melanocytic 
nests. d Immunohistochemistry showing S-100 protein-positive staining in melanocytic nevus cells.  
e, f CD3+ and CD4+ lymphocytic infiltrate at the dermoepidermal junction and papillary dermis. 
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